Incyte Reports Jakafi Data Continues to Show Improved Overall Survival for Patients with Myelofibrosis at ASH
December 09, 2013 at 12:48 PM EST
Incyte Corporation (Nasdaq: INCY ) announced today that more than 35 analyses from clinical studies of Jakafi® (ruxolitinib) were presented at the 2013 American Society of Hematology (ASH) Annual